Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors

(2015) J. R. Baird et al.   CANCER RESEARCH

Challenges and future perspectives of T cell immunotherapy in cancer

(2015) Maria Teresa P. de Aquino et al.   IMMUNOLOGY LETTERS

Toll-like receptor 7/8 agonist, R848, exhibits antitumoral effects in a breast cancer model

(2015) TAO YIN et al.   Molecular Medicine Reports

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

(2015) Juan Fu et al.   Science Translational Medicine

Synthetic biology in cell-based cancer immunotherapy

(2015) Deboki Chakravarti et al.   TRENDS IN BIOTECHNOLOGY

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Harnessing the Microbiome to Enhance Cancer Immunotherapy

(2015) Michelle H. Nelson et al.   Journal of Immunology Research

Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma

(2014) Raymond Yung et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

(2014) Seng-Ryong Woo et al.   IMMUNITY

STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer

(2014) D. Chandra et al.   Cancer Immunology Research

STING-Dependent Recognition of Cyclic di-AMP Mediates Type I Interferon Responses during Chlamydia trachomatis Infection

(2013) J. R. Barker et al.   mBio

Modified STING-activating cyclic dinucleotide derivatives significantly enhance the anti-tumor activity of therapeutic vaccines

(2013) Meredith Leong et al.   Journal for ImmunoTherapy of Cancer

STING and the innate immune response to nucleic acids in the cytosol

(2012) Dara L Burdette et al.   NATURE IMMUNOLOGY

Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice – Role of toll-like-receptor 4 expressed on host cells

(2011) Anne-Kristin Vahle et al.   CANCER LETTERS

Cyclic di-nucleotides: new era for small molecules as adjuvants

(2011) Rimma Libanova et al.   Microbial Biotechnology

Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents

(2010) Qi Zeng et al.   HUMAN GENE THERAPY

TheN-Ethyl-N-Nitrosourea-InducedGoldenticketMouse Mutant Reveals an Essential Function ofStingin theIn VivoInterferon Response toListeria monocytogenesand Cyclic Dinucleotides

(2010) John-Demian Sauer et al.   INFECTION AND IMMUNITY

Patterns of Pathogenesis: Discrimination of Pathogenic and Nonpathogenic Microbes by the Innate Immune System

(2009) Russell E. Vance et al.   Cell Host & Microbe

Recent Advances in Cancer Therapy: An Overview

(2009) A. Urruticoechea et al.   CURRENT PHARMACEUTICAL DESIGN

A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP

(2009) Sarah M. McWhirter et al.   JOURNAL OF EXPERIMENTAL MEDICINE